

11 March 2026

**Cambridge Cognition Holdings plc**  
("Cambridge Cognition", the "Company" or the "Group")

**Cambridge Cognition Investment, Monument Therapeutics, Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis**

**Cambridge UK, March 11, 2026** - Cambridge Cognition (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, reports that Monument Therapeutics Limited ("Monument"), in which the Group has a 20% shareholding, has announced the dosing of the first patient in its clinical trial with MT1988, to treat patients at clinical high risk (CHR) for psychosis.

The study is being conducted in collaboration with the Foundation for the National Institutes of Health (FNIH) as part of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program. This trial marks a major step forward in developing treatment options for people at risk of schizophrenia.

The randomised, placebo-controlled, proof-of-principle study will enrol 150 CHR participants who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period. The trial will evaluate the potential of MT1988 to improve cognitive symptoms in CHR individuals, incorporating a range of clinical and cognitive biomarkers. This approach is designed to assess not only therapeutic effects but also the potential of these biomarkers to predict and monitor treatment response.

Cambridge Cognition's proprietary digital cognitive assessment technologies supported the early development of MT1988 and were instrumental in establishing the foundational biomarker strategy for Monument.

**Sheryl Caswell, Chief Development Officer of Monument Therapeutics** said *"Dosing our first patient marks a pivotal moment for Monument Therapeutics and for people at risk of developing psychosis, because, despite the significant impact of this early stage of illness, there are currently no approved pharmacological treatments for the CHR population."*

**Rob Baker, Chief Executive Officer - Cambridge Cognition** said, *"We congratulate our colleagues at Monument for achieving this milestone in MT1988's development. Treatment of the first patient represents a significant value inflection point for Monument. We believe using both biological biomarkers and Cambridge Cognition's digital assessments of cognitive function to assess MT1988 will provide insights into the underlying biology and also capture observable changes in cognitive function."*

**NOTES TO EDITORS**

**ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™**

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the **CANTAB** and **Winterlight** brands. These assessments are designed to:

- require minimal specialist administration
- deliver objective results in real time or shortly after completion
- reduce administrator bias
- support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments

**CANTAB Pathway™** is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:

- **CANTAB One™** - a brief assessment of overall cognitive function
- **CANTAB Insight™** - a three-task battery providing deeper insight across five cognitive sub-domains
- **CANTAB Plus™** - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: [www.cambridgecognition.com](http://www.cambridgecognition.com)

#### **About Monument Therapeutics:**

Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique and novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with the innovative drugs that it is developing.

For more information, please visit [www.monumenttx.com](http://www.monumenttx.com).

#### **About the Foundation for the National Institutes of Health:**

The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the U.S. Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit [fnih.org](http://fnih.org).

#### **About the Accelerating Medicines Partnership®:**

Launched in 2014 and managed by the FNIH, the Accelerating Medicines Partnership (AMP) program brings together the National Institutes of Health, U.S. Food and Drug Administration, biomedical and life sciences companies, nonprofits, patient-focused groups, and other organizations to transform the current model for developing new diagnostics and treatments. Using cutting-edge scientific approaches and broad sharing of research data, all AMPs seek to improve understanding of disease pathways, facilitate better selection of targets for drug development, and streamline processes for bringing new treatments to patients. To learn more about AMP, visit [fnih.org/AMP](http://fnih.org/AMP).

#### **Enquiries:**

<b>Cambridge Cognition Holdings plc</b>	Tel: +44 1223 810700
Rob Baker, Chief Executive Officer	<a href="mailto:press@camcog.com">press@camcog.com</a>
Ronald Openshaw, Chief Financial Officer	
Adam Michael, Head of Corporate Communications	
<b>Panmure Liberum Limited (NOMAD &amp; Joint Broker)</b>	Tel: +44 20 7886 2968
Will Goode / Mark Rogers / Freddy Crossley	(Corporate Finance)
Rupert Dearden	(Corporate Broking)
<b>Singer Capital Markets Limited (Joint Broker)</b>	Tel: +44 20 7496 3000
Amber Higgs / James Serjeant / Daniel Ingram	

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCMZGMFNGNGVZM